Total Project Cost: $13 million
“GE Capital” Financing: $3 million
Partner Equity: $2 million
EB-5 Investors: $8 million
Number of EB-5 Investors: 16
Investment Amount per Unit: $500,000
Administrative Fee: $38,000 per unit
Annual Interest Rate: 2% (paid annually)
Project Introduction:
NCM USA BRONX will be the first PET radiopharmaceutical base in New York City, planning to develop a state-of-the-art PET (Positron Emission Tomography) radiopharmaceutical manufacturing and distribution network in New York City and the surrounding areas. The project will construct a 9,600-square-foot NCM facility to manufacture FDG (Fluorodeoxyglucose), a radiopharmaceutical used for PET/CT imaging to diagnose and detect cancer, heart disease, and brain disorders.
NCM USA BRONX will also manufacture newly introduced compounds, providing a competitive advantage over institutions unable to produce these compounds. NCM USA BRONX will integrate financing from General Electric, principal equity, and foreign investment under the guidance of EB-5 policies.
Project Advantages:
Low Risk: NCM USA BRONX is a relatively low-risk EB-5 project with only 16 investors and a clearly defined exit strategy!
Fund Security: NCM USA BRONX features a dynamic and secure capital structure, including financing from the global industrial and financial leader, General Electric (GE), and guarantees from other funding sources!
Huge Market Potential: NCM USA BRONX will be the first PET radiopharmaceutical base in New York City. Its products and the PET scanners installed in New York City face significant demand. The radiopharmaceutical industry is typically recession-resistant and does not rely on the U.S. economy!
High-Quality Collateral: NCM USA BRONX has high-quality mortgage guarantees to protect investors' capital!
Creation of Sufficient Jobs: According to the job calculation formula, NCM USA BRONX will create a total of 203.7 direct and indirect jobs, exceeding the USCIS requirement by 27%.
Famous Immigration Counsel: Mr. Klasko, Chairman of the EB-5 Committee of the American Immigration Lawyers Association, has been retained as the immigration attorney for the project.
Project Team Strengths: Anwer Rizvi, President of NCM USA BRONX, is a founder and former president of the industry leader IBA Molecular.
Sources and Uses of Project Funds:
Project Financial Forecasts:
Job Creation by the Project:
Exit Strategy:
Repay the loan through cash flow from operations and/or refinancing of the project, and distribute funds to investment members based on their capital contribution ratios.
Accrue interest at an estimated non-compounded annual interest rate of 2%, paid to investment immigration clients once per year.
What are PET Radiopharmaceuticals?
Imaging scanners (PET/CT scanners) use specially designed drugs to diagnose various diseases, including:
. Cancer
. Brain diseases (Alzheimer's, etc.)
. Heart diseases
How PET Radiopharmaceuticals are used
Radioactive material (F-18) FDG is produced by a cyclotron machine.
(F-18) FDG is created by combining radioactive material with metabolic glucose (sugar).
FDG typically has a maximum effective duration of 8-10 hours; therefore, it must be injected into the patient's body in a timely manner and scanned using a PET/CT scanner.
FDG accumulates more in cancerous cells than in non-cancerous cells, which appears as a “bright spot” on the PET/CT scanner. Doctors can interpret these images to determine which part of the body/organs are cancerous.
Advantages of PET/CT scans over traditional scans
Traditional PET scans show areas of abnormal activity but do not pinpoint the exact location.
Traditional CT scan images show the precise structure of the human body but do not show functional chemical processes.
PET/CT scans fuse functional body images with structural body images into PET/CT images. Doctors can now see the affected area and know exactly where the activity is occurring, thereby helping to make appropriate treatment decisions.
Future Radiopharmaceutical and PET demand
Sales of PET radiopharmaceuticals (FDG) were $400 million in 2010 and are expected to grow to $4 billion by 2018.
PET Radiopharmaceutical Industry Forecast
Many products will be brought to market within the next 1-4 years.
Over 25 new radiopharmaceuticals are currently undergoing clinical trials in the United States.
Some of these new radiopharmaceutical compounds will be used to diagnose cancer (oncology), brain diseases (neurology), and heart disease (cardiology).
NCM USA Competitive Advantage in the Radiopharmaceutical Market
Developing an advanced, high-capacity manufacturing and distribution network in New York City, the largest market in the United States.
Capability to produce a variety of compounds (not just FDG) as new compounds enter the market within 2-4 years.
Advanced GE cyclotron technology to meet the growing demand for FDG manufacturing.
State-of-the-art facility compliant with new regulatory requirements.
NCM USA will be a fully automated facility with lower production costs.
Anwer Rizvi, a key principal of NCM USA, is a founder of IBA Molecular.
[Note]:
1. All project information shall be subject to the official offering documents;
2. EB-5 investment involves risks, and applicants should make independent judgments.
